Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Insight Into Reduction of Wakefulness by Suvorexant in Patients With Insomnia: Analysis of Wake Bouts
Vladimir Svetnik, Ellen Snyder, Peining Tao, et al.
SLEEP (2017) Vol. 41, Iss. 1
Open Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

The neurobiological basis of narcolepsy
Carrie E. Mahoney, Andrew C. Cogswell, Igor J. Koralnik, et al.
Nature reviews. Neuroscience (2018) Vol. 20, Iss. 2, pp. 83-93
Open Access | Times Cited: 216
Orexin Receptor Antagonists as Emerging Treatments for Psychiatric Disorders
Ying Han, Kai Yuan, Yongbo Zheng, et al.
Neuroscience Bulletin (2019) Vol. 36, Iss. 4, pp. 432-448
Open Access | Times Cited: 77
Targeting Orexin Receptors for the Treatment of Insomnia: From Physiological Mechanisms to Current Clinical Evidence and Recommendations
Maria P. Mogavero, Alessandro Silvani, Giuseppe Lanza, et al.
Nature and Science of Sleep (2023) Vol. Volume 15, pp. 17-38
Open Access | Times Cited: 23
Sleep Physiology, Circadian Rhythms, Waking Performance and the Development of Sleep-Wake Therapeutics
Derk‐Jan Dijk, Hans‐Peter Landolt
Handbook of experimental pharmacology (2019), pp. 441-481
Open Access | Times Cited: 55
Narcolepsy
Lucie Barateau, Fabio Pizza, Giuseppe Plazzi, et al.
Journal of Sleep Research (2022) Vol. 31, Iss. 4
Closed Access | Times Cited: 35
Hypocretin/Orexin, Sleep and Alzheimer’s Disease
Yves Dauvilliers
Monographs in clinical neuroscience/Frontiers of neurology and neuroscience/Monographs in neural sciences (2021), pp. 139-149
Open Access | Times Cited: 33
Suvorexant, a Novel Dual Orexin Receptor Antagonist, for the Management of Insomnia
Andrew Hogyu Han, Caroline R. Burroughs, Evan P. Falgoust, et al.
Health psychology research (2023) Vol. 10, Iss. 5
Open Access | Times Cited: 13
The interaction between orexin, sleep deprivation and Alzheimer’s disease: Unveiling an Emerging Connection
Masoumeh Kourosh‐Arami, Mahdi Ramezani, Alireza Komaki‬
The Journal of Physiological Sciences (2025) Vol. 75, Iss. 1, pp. 100004-100004
Open Access
Orexin receptor antagonists for the treatment of insomnia and potential treatment of other neuropsychiatric indications
W. Joseph Herring, Thomas Roth, Andrew D. Krystal, et al.
Journal of Sleep Research (2018) Vol. 28, Iss. 2
Closed Access | Times Cited: 44
Association of CSF orexin-A levels and nocturnal sleep stability in patients with hypersomnolence
Lucie Barateau, Régis Lopez, Sofiène Chenini, et al.
Neurology (2020) Vol. 95, Iss. 21
Open Access | Times Cited: 35
Stability of nocturnal wake and sleep stages defines central nervous system disorders of hypersomnolence
Kiran Maski, Alicia Colclasure, Elaina Little, et al.
SLEEP (2021) Vol. 44, Iss. 7
Open Access | Times Cited: 31
Optical probing of orexin/hypocretin receptor antagonists
Shi‐Bin Li, Natalie Nevárez, William J. Giardino, et al.
SLEEP (2018) Vol. 41, Iss. 10
Open Access | Times Cited: 32
Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice
Carrie E. Mahoney, Takatoshi Mochizuki, Thomas E. Scammell
SLEEP (2019) Vol. 43, Iss. 6
Open Access | Times Cited: 30
Sleep structure in patients with COMISA compared to OSA and insomnia
Bernice M. Wulterkens, Lieke WA Hermans, Pedro Fonseca, et al.
Journal of Clinical Sleep Medicine (2023) Vol. 19, Iss. 6, pp. 1051-1059
Closed Access | Times Cited: 10
Number, Duration, and Distribution of Wake Bouts in Patients with Insomnia Disorder: Effect of Daridorexant and Zolpidem
Tobias Di Marco, Thomas E. Scammell, Michael Meinel, et al.
CNS Drugs (2023) Vol. 37, Iss. 7, pp. 639-653
Open Access | Times Cited: 10
Effect of daridorexant on sleep architecture in patients with chronic insomnia disorder: a pooled post hoc analysis of two randomized phase 3 clinical studies
Tobias Di Marco, Ina Djonlagic, Yves Dauvilliers, et al.
SLEEP (2024) Vol. 47, Iss. 11
Open Access | Times Cited: 2
Effect of suvorexant on event-related oscillations and EEG sleep in rats exposed to chronic intermittent ethanol vapor and protracted withdrawal
Manuel Sánchez-Alavez, Jessica Benedict, Derek N. Wills, et al.
SLEEP (2019) Vol. 42, Iss. 4
Open Access | Times Cited: 22
The dual orexinergic receptor antagonist DORA-22 improves the sleep disruption and memory impairment produced by a rodent insomnia model
Mackenzie C. Gamble, Fumi Katsuki, John G. McCoy, et al.
SLEEP (2019)
Open Access | Times Cited: 21
Sleep and pain in humans with fibromyalgia and comorbid insomnia: double-blind, crossover study of suvorexant 20 mg versus placebo
Timothy Roehrs, Dana Withrow, Gail Koshorek, et al.
Journal of Clinical Sleep Medicine (2020) Vol. 16, Iss. 3, pp. 415-421
Open Access | Times Cited: 19
A double-blind, randomized, placebo-controlled trial of suvorexant for the treatment of vasomotor symptom-associated insomnia disorder in midlife women
Shadab A. Rahman, Margo Nathan, Aleta Wiley, et al.
SLEEP (2022) Vol. 45, Iss. 3
Open Access | Times Cited: 12
Chronotherapeutic efficacy of suvorexant on sleep quality and metabolic parameters in patients with type 2 diabetes and insomnia
Fukumi Yoshikawa, Fumika Shigiyama, Yukio Ando, et al.
Diabetes Research and Clinical Practice (2020) Vol. 169, pp. 108412-108412
Closed Access | Times Cited: 16
The Discovery of Suvorexant: Lessons Learned That Can Be Applied to Other CNS Drug Development Efforts
Jason M. Uslaner, W. Joseph Herring, Paul J. Coleman
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 1, pp. 161-168
Open Access | Times Cited: 13
<p>Single-use suvorexant for treating insomnia during overnight polysomnography in patients with suspected obstructive sleep apnea: a single-center experience</p>
Takuma Matsumura, Jiro Terada, Chikara Yoshimura, et al.
Drug Design Development and Therapy (2019) Vol. Volume 13, pp. 809-816
Open Access | Times Cited: 5
The Dual Orexin Receptor Antagonist DORA-22 Improves Mild Stress-induced Sleep Disruption During the Natural Sleep Phase of Nocturnal Rats
Mackenzie C. Gamble, Fumi Katsuki, John G. McCoy, et al.
Neuroscience (2021) Vol. 463, pp. 30-44
Closed Access | Times Cited: 4
Characteristics of psychiatric patients with nightmares after suvorexant administration: A retrospective study
Kazuya Yasuda, Yoji Hirano, Ryuichiro Takeda, et al.
Neuropsychopharmacology Reports (2024)
Closed Access
Page 1 - Next Page

Scroll to top